- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 02:29 | OS Therapies Launches Subsidiary To Commercialize Canine Osteosarcoma Treatment | 1 | RTTNews | ||
| 07.05. | OS Therapies secures patent for cancer immunotherapy tech | 1 | Investing.com | ||
| OS THERAPIES Aktie jetzt für 0€ handeln | |||||
| 07.05. | OS Therapies sichert Patent für Krebsimmuntherapie-Technologie | - | Investing.com Deutsch | ||
| 10.04. | OS Therapies Announces Positive Data for OST-HER2 in the Treatment of Unresected Osteosarcoma in Dogs Opening the Potential for Use as Front-Line Therapy in Humans | 257 | Newsfile | Yet to be published data from clinical study combining OST-HER2 with palliative radiation in dogs with unresected, primary osteosarcoma shows clinical and radiographic arrest of the primary tumor,... ► Artikel lesen | |
| 09.04. | OS Therapies Inc - 8-K, Current Report | 5 | SEC Filings | ||
| 09.04. | OS Therapies übernimmt Immuntherapie-Vermögenswerte von Advaxis | 1 | Investing.com Deutsch | ||
| 09.04. | OS Therapies acquires Advaxis Immunotherapies assets | 1 | Investing.com | ||
| 31.03. | OS Therapies Inc - 10-K, Annual Report | - | SEC Filings | ||
| 31.03. | OS Therapies macht Fortschritte mit OST-HER2 für Osteosarkom | 1 | Investing.com Deutsch | ||
| 31.03. | OS Therapies advances OST-HER2 for osteosarcoma | 3 | Investing.com | ||
| 11.03. | OS Therapies, Inc.: OS Therapies Schedules United Kingdom's Medicines and Healthcare products Regulatory Agency's (MHRA) Scientific Advice Meeting in the Third Quarter of 2025 for Review of its OST-HER2 Immunotherapy Candidate for Osteosarcoma | 290 | Business Wire | OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced that it has scheduled a Scientific... ► Artikel lesen | |
| 28.02. | Calidi Biotherapeutics and OS Therapies Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV | 358 | ACCESS Newswire | ORLANDO, FLORIDA / ACCESS Newswire / February 28, 2025 / RedChip Companies will air interviews with Calidi Biotherapeutics, Inc. (NYSE American:CLDI) and OS Therapies Inc. (NYSE American:OSTX) on the... ► Artikel lesen | |
| 24.02. | OS Therapies sets up subsidiary to seek ADC joint ventures with US, China peers | 2 | FierceBiotech | ||
| 24.02. | OS Therapies gründet Tochtergesellschaft für Fortschritte bei Krebsmedikamenten | 1 | Investing.com Deutsch | ||
| 24.02. | OS Therapies creates subsidiary for cancer drug advances | 1 | Investing.com | ||
| 14.02. | Small-Cap OS Therapies Inks Commercial Manufacture Agreements For Lead Cancer Drug For Rare Type Of Bone Cancer | 2 | Benzinga.com | ||
| 14.02. | OS Therapies bereitet sich auf FDA-Treffen zu Krebsmedikament vor | 2 | Investing.com Deutsch | ||
| 14.02. | OS Therapies gears up for FDA meeting on cancer drug | 1 | Investing.com | ||
| 04.02. | OS Therapies gears up for osteosarcoma drug approval | 1 | Investing.com | ||
| 04.02. | OS Therapies bereitet sich auf die Zulassung eines Osteosarkom-Medikaments vor | 1 | Investing.com Deutsch |
Seite:
1 2 3 Weiter >>
48 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CRISPR THERAPEUTICS | 33,400 | +2,45 % | Are Investors Making a Big Mistake Dumping Shares of CRISPR Therapeutics? | ||
| IMMUNIC | 0,910 | +2,36 % | IMMUNIC, INC. - 10-Q, Quarterly Report | ||
| PHIO PHARMACEUTICALS | 1,780 | 0,00 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update | Clinical trial advances for INSTASYL siRNA lead product candidate PH-762 4th Cohort enrolling and treating patients in on-going clinical studyMarlborough, Massachusetts--(Newsfile Corp. - May 15, 2025)... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 11,630 | 0,00 % | Arcturus stops work on early-stage vaccine programs in effort to 'streamline resources' | ||
| PROTALIX BIOTHERAPEUTICS | 1,470 | -0,68 % | Protalix BioTherapeutics Inc. Q1 Loss Narrows | JERUSALEM (dpa-AFX) - Protalix BioTherapeutics Inc. (PLX) released Loss for first quarter of -$3.62 millionThe company's earnings came in at -$3.62 million, or -$0.05 per share. This compares... ► Artikel lesen | |
| SCILEX | 4,120 | 0,00 % | Scilex zeigt deutliche Umsatzrückgänge trotz EPS-Verbesserung | ||
| CHECKPOINT THERAPEUTICS | 3,675 | -1,08 % | Checkpoint Therapeutics, Inc: Checkpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate Updates | UNLOXCYT (cosibelimab-ipdl) approved by U.S. FDA in December 2024 as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma Special meeting of stockholders to vote on... ► Artikel lesen | |
| MEIRAGTX | 4,680 | +4,00 % | MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson's Disease | - This RMAT designation is based on data from 3 clinical studies demonstrating the potential benefit of AAV-GAD as a one-time treatment for Parkinson's disease - RMAT designation includes the benefits... ► Artikel lesen | |
| INVIVYD | 0,708 | 0,00 % | Invivyd Reports First Quarter 2025 Financial Results and Recent Business Highlights | PEMGARDA (pemivibart) net product revenue of $11.3 million reported for Q1 2025, influenced by planned transition (Jan/Feb) from a contracted to an internalized sales forcePEMGARDA revenue re-acceleration... ► Artikel lesen | |
| UNICYCIVE THERAPEUTICS | 0,547 | 0,00 % | Unicycive Therapeutics, Inc.: Unicycive Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update | - Oxylanthanum carbonate (OLC) New Drug Application (NDA) for hyperphosphatemia in chronic kidney disease patients on dialysis under review by FDA with PDUFA target action date of June 28, 2025; ongoing... ► Artikel lesen | |
| TEMPUS AI | 62,60 | 0,00 % | Tempus AI: Starkes Wachstum - Verluste steigen jedoch weiter an | CHICAGO, Illinois (IT-Times) - Das Diagnose-Technologie-Unternehmen Tempus AI hat seine Ergebnisse für das erste Quartal 2025 bekannt gegeben und ein rasantes Wachstum vorgelegt. Tempus AI - Aktie:... ► Artikel lesen | |
| SPRINGWORKS THERAPEUTICS | 46,075 | 0,00 % | Laufende Fusionskontrollverfahren: Merck KGaA, Darmstadt; Erwerb sämtlicher Anteile an und der alleinigen Kontrolle über SpringWorks Therapeutics, Inc., Stamford, Connecticut, USA | Datum der Anmeldung:08.05.2025Aktenzeichen:B3-54/25Unternehmen:Merck KGaA, Darmstadt; Erwerb sämtlicher Anteile an und der alleinigen Kontrolle über SpringWorks Therapeutics, Inc., Stamford, Connecticut... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,250 | 0,00 % | Recursion Pharmaceuticals Plunges 22% in May: How to Play the Stock | ||
| QIAGEN | 37,800 | +0,49 % | UBS stuft QIAGEN NV auf 'Neutral' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat Qiagen auf "Neutral" mit einem Kursziel von 48 US-Dollar belassen. Den hohen Margen im Geschäft mit Laborverbrauchsmaterialien stehe sein fehlendes... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 23,070 | 0,00 % | Summit Therapeutics Q1 2025 slides: Strong cash position supports advancing Ivonescimab pipeline |
Das Unternehmen OS THERAPIES INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 1,620 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OS THERAPIES INC finden Sie auf Wallstreet Online.